Bayhill Therapeutics Inc.
This article was originally published in Start Up
Executive SummaryBy using DNA that encodes for self-antigens, Bayhill Therapeutics hopes to dampen or terminate the activities of TH1 helper cells involved in tissue destruction in autoimmune diseases, specifically multiple sclerosis, while at the same time activating TH2 cells to help combat the disease.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.